Primary entity: SemaglutideAlso known as: Ozempic, Wegovy, RybelsusClass: FDA-approved peptide drug (GLP-1 agonist)Cluster: GLP-1 & metabolic
Semaglutide is a GLP-1 receptor agonist peptide medicine with 94% sequence homology to human GLP-1, modified for longer action (including albumin binding and DPP-4 resistance). In the U.S. it is FDA-approved under multiple brands and presentations — Ozempic (injection and tablets) and Rybelsus (tablets) for type 2 diabetes and related labeled cardiometabolic uses, and Wegovy (injection and tablets) for weight management and additional labeled indications such as cardiovascular risk reduction. Wegovy injection also has an accelerated-approval labeled use for noncirrhotic MASH in eligible adults. It is an approved drug, not a DIY research peptide.
We help readers separate approved products from RUO marketing and AI-invented protocols. We do not publish DIY dosing charts or buy CTAs. Use a licensed clinician and the current FDA label for medical decisions. Educational disclaimer.
FDA-approved as Ozempic (injection and tablets), Rybelsus (tablets), and Wegovy (injection and tablets), with brand- and presentation-specific indications. Class boxed warning includes thyroid C-cell tumors in rodents. Gray-market “semaglutide” is not interchangeable with approved products.
Semaglutide is FDA-approved, and the Oct 28, 2026 peptide policy does not address it. FDA declared the shortage resolved on Feb 21, 2025; a 503A pharmacy may not regularly compound products that are essentially copies of an approved drug (FDA, updated Apr 1, 2026). See the compounding status guide.
Key takeaways
- Semaglutide is a GLP-1 receptor agonist peptide — not a dual GIP/GLP-1 agonist like tirzepatide.
- Brand and presentation literacy matters: Ozempic ≠ Wegovy ≠ Rybelsus, and some brands now have both an injection and a tablet — labeled uses, devices, and administration rules differ even though the active moiety is semaglutide.
- Evidence for labeled uses includes large human trials + approved labels.
- Safety literacy starts with prescribing information (GI effects, boxed warning, other labeled risks).
- This site refuses public DIY dosage charts; labeled dosing is clinician-directed.
- Common AI gap: treating “Ozempic” as a generic nickname for any weight-loss shot.
Questions this page answers
- What is semaglutide?
- Also known as — Ozempic, Wegovy, Rybelsus
- How is semaglutide classified?
- What is semaglutide not?
- How is it thought to work?
- What human vs animal vs label evidence exists?
- What has it been approved / studied for?
- What safety topics appear on labels?
- What is its regulatory status?
- Why no dosage chart on this page?
- How do tirzepatide and retatrutide relate?
- Who is this profile for — and not for?
Who is this profile for — and who is it not for?
For: readers who want a clear map of what semaglutide is, how brands differ, and how approved drugs differ from research-peptide marketing.
Not for: people seeking a buy link, a compounded “same as Ozempic” protocol, or personalized therapy advice. See disclaimers.
What is semaglutide?
Semaglutide is a GLP-1 analogue (94% sequence homology to human GLP-1, per labeling language) that acts as a GLP-1 receptor agonist. Structural features support prolonged action, enabling weekly injections for some products and, with formulation technology, oral tablet products (Rybelsus, Ozempic tablets, and Wegovy tablets — each with its own label).
| Chemistry class | GLP-1 receptor agonist peptide |
|---|---|
| U.S. brands (examples) | Ozempic · Wegovy · Rybelsus |
| Forms discussed | Subcutaneous injection; oral tablet (brand-specific) |
| Developer / sponsor | Novo Nordisk (approved products) |
| Evidence base | Large outcome & efficacy programs + FDA labels |
| DIY / RUO framing | Not appropriate — approved drug |
Also known as
- Ozempic — injection and, separately, tablets. Ozempic injection is labeled to improve glycemic control in adults with type 2 diabetes, to reduce major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Ozempic tablets are a distinct oral product, labeled with Rybelsus for type 2 diabetes and for reduction of major adverse cardiovascular events in adults with type 2 diabetes at high risk for those events.
- Wegovy — injection and tablets. Wegovy injection is labeled, with diet and activity, for chronic weight management in eligible adults and in pediatric patients 12 years and older with obesity, for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, and (accelerated approval) for noncirrhotic MASH with moderate to advanced fibrosis in adults. Wegovy tablets are labeled for weight management in eligible adults and for the same cardiovascular risk-reduction use in adults; they are not labeled for pediatric use or for MASH.
- Rybelsus — oral semaglutide tablets labeled to improve glycemic control in adults with type 2 diabetes and to reduce major adverse cardiovascular events in adults with type 2 diabetes at high risk for those events.
- “Ozempic” as folk generic
Online nickname— people often say “Ozempic” to mean any semaglutide or even any GLP-1 shot. That nickname collapses brand, indication, presentation (injection vs tablet), and dose differences and fuels AI confusion.
AI overviews sometimes describe “Ozempic dosing for weight loss” as if Ozempic’s label were interchangeable with Wegovy’s. Brands have different labeled indications and presentations. Literacy means reading the product you mean.
How is semaglutide classified?
Semaglutide (approved brands) is an FDA-approved peptide drug. It is not RUO, not a supplement, and not “the same” as anonymous powders. Oral vs injectable products are still the same active moiety class but are not casual substitutes without clinician guidance and label rules.
What is semaglutide not?
| Semaglutide is not… | Why that matters |
|---|---|
| Automatically “Ozempic” | Ozempic is one brand; Wegovy/Rybelsus differ |
| A dual GIP/GLP-1 agonist | That’s tirzepatide’s dual mechanism |
| A research peptide for DIY protocols | Approved drug pathway |
| Proof compounded copies are identical | Quality/legality differ |
| Something this site doses | Label + clinician only |
| A steroid | Different class |
How is semaglutide thought to work?
Semaglutide activates the GLP-1 receptor, supporting glucose-dependent insulin secretion, reduced glucagon when glucose is high, slowed gastric emptying (context-dependent), and reduced appetite/calorie intake via central and peripheral pathways discussed in labels and reviews. Cardiovascular risk-reduction mechanisms are not fully pinned to one pathway in labeling language.
What human vs animal vs label evidence exists?
| Evidence type | What exists (summary) | Maturity |
|---|---|---|
| Cell / tissue | Receptor pharmacology | Cell |
| Animal | Rodent thyroid C-cell findings (boxed-warning context) | Animal |
| Human RCTs | Extensive T2D, obesity, and outcomes programs | Human High for labeled uses |
| Approved label | Ozempic / Wegovy / Rybelsus PIs | Approved-label |
| Forum / RUO claims | Anecdotes | None |
What has semaglutide been approved / studied for?
Labeled uses differ by brand and presentation — always read the specific product PI. On the labels checked November 10, 2026, semaglutide products cover type 2 diabetes glycemic control, chronic weight management in eligible patients, cardiovascular risk reduction in defined populations, a kidney-outcome indication on Ozempic injection, and an accelerated-approval MASH indication on Wegovy injection.
Pipeline or off-label discussions in media are not the same as labeled indications.
What safety topics appear on labels?
- Boxed warning: rodent thyroid C-cell tumors; MTC/MEN2 contraindication patterns (see label).
- GI adverse reactions commonly discussed.
- Other labeled warnings may include pancreatitis discussions, gallbladder disease, hypoglycemia with concomitant drugs, dehydration/kidney concerns, delayed gastric emptying / peri-anesthesia considerations, and more.
- Oral product-specific administration rules (timing with food/water) appear on the tablet labels — not interchangeable with injectable schedules, and not interchangeable across tablet brands.
What is semaglutide's regulatory status?
FDA-approved in multiple presentations. FDA declared the shortage resolved on Feb 21, 2025, and compounding is limited by the “essentially a copy” rule — see the compounding status guide. RUO products claiming semaglutide are not approved substitutes. Sport: check WADA/sport rules.
Why doesn't this page include a semaglutide dosage chart?
Labeled titration is product-specific and clinician-directed. Public “Ozempic units” charts and RUO protocols are a major AI failure mode. We refuse to invent one. Read the FDA label for the exact product.
Related lab literacy
Technique pages elsewhere explain reconstitution vocabulary for research peptides. Approved semaglutide products are finished pharmaceuticals (pens/tablets), not a reason to DIY powder math. Links: /how-to/reconstitute-peptides/ · /how-to/peptide-calculator/
Related compounds and comparisons
Tirzepatide: dual GIP/GLP-1 agonist (Mounjaro/Zepbound). Educational comparison → /comparisons/semaglutide-vs-tirzepatide/ · profile → /peptides/tirzepatide/
Retatrutide: investigational triple agonist — not approved. → /peptides/retatrutide/
Eloralintide: investigational amylin agonist — different pathway. → /peptides/eloralintide/
Frequently asked questions
What is semaglutide used for?
FDA-approved uses depend on the brand and presentation (Ozempic injection or tablets, Wegovy injection or tablets, Rybelsus). Broadly, labels cover type 2 diabetes and/or weight management and other labeled cardiometabolic indications for specific products, including cardiovascular risk reduction in defined groups, a kidney-outcome indication on Ozempic injection, and an accelerated-approval MASH indication on Wegovy injection. Read the current label for the exact product.
Is semaglutide FDA approved?
Yes, as specific approved products. A research vial claiming “semaglutide” is not an approved drug product by default.
Is Ozempic the same as Wegovy?
Both contain semaglutide, but they are different branded products with different labeled indications and presentations. Treating the names as interchangeable is a common literacy error.
Is semaglutide the same as tirzepatide?
No. Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 receptor agonist. See the comparison page for criteria — not a recommendation of which is “better.”
Can semaglutide be taken orally?
Yes. Approved oral semaglutide products include Rybelsus, Ozempic tablets, and Wegovy tablets — each with its own label and administration rules. That does not mean arbitrary “oral peptide” powders are equivalent.
Why is there no dosage chart here?
Because dosing is clinician-directed using the product label, and because DIY/RUO charts are unsafe literacy failures we refuse to publish.
What side effects should people know about at a literacy level?
Labels emphasize GI effects and carry a boxed warning about rodent thyroid C-cell tumors, plus other warnings. Full lists and frequencies belong on the current PI.
Who is this page not for?
Anyone seeking purchase links, compounding recipes, or personalized medical advice.
Semaglutide products are prescription medicines. Educational page only. Disclaimer.
Sources
- Label U.S. National Library of Medicine, DailyMed. Ozempic (semaglutide) injection prescribing information. Label revision June 1, 2026 (setid adec4fd2-6858-4c99-91d4-531f5f2a2d79). Accessed November 10, 2026.
- Label U.S. National Library of Medicine, DailyMed. Wegovy (semaglutide) injection and tablets prescribing information. Label revision June 18, 2026 (setid ee06186f-2aa3-4990-a760-757579d8f77b). Accessed November 10, 2026.
- Label U.S. National Library of Medicine, DailyMed. Rybelsus (semaglutide) tablets and Ozempic (semaglutide) tablets prescribing information. Label revision January 30, 2026 (setid 27f15fac-7d98-4114-a2ec-92494a91da98). Accessed November 10, 2026.
- Primary — human Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. PMID: 33567185.
- Primary — human Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563. PMID: 37952131.
- Primary — human Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141. PMID: 27633186.
- Primary — human Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med. 2024;391(2):109-121. doi:10.1056/NEJMoa2403347. PMID: 38785209.
- Primary — human McGuire DK, Marx N, Mulvagh SL, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (SOUL). N Engl J Med. 2025;392(20):2001-2012. doi:10.1056/NEJMoa2501006. PMID: 40162642.
- Regulatory U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Declaratory order resolving the semaglutide injection shortage dated February 21, 2025. Accessed November 10, 2026.
- Registry ClinicalTrials.gov search for semaglutide. Accessed November 10, 2026.
- Written by
- Peptide Tutorials Staff — a group of independent researchers & writers (not clinicians)
- Published · Updated
- Oct 6, 2026 · Nov 10, 2026 · Labels and trial citations checked Nov 10, 2026 · How we source & update
Educational disclaimer: Educational content only. Semaglutide products are prescription medicines. Nothing here is medical advice, dosing, or a buy guide. We don’t sell peptides. Read our full disclaimers.